0611/26SCR019-18/R6RGB
Media Highlights
From the 2026 ASCO® Annual Meeting
3
Continued ➔
Media Outlet Date Article / Coverage
The ASCO Post 6/3/26 Erika P. Hamilton, MD, FASCO, on HER2-Positive Metastatic
Breast Cancer: Maintenance Therapy Comparison
OncLive 5/6/26 ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read
up on the Insights to Know Before You Go
OncLive 5/7/26 ASCO 2026 TNBC Deep Dive: Breast Cancer Experts
Preview Practice-Informing Studies
OncLive 5/21/26 Survival Gains Confirmed: Full KEYNOTE-225 Data Set
to Redefine Treatment Standards in Early-Stage TNBC at
ASCO 2026
Oncology Education 6/3/26 ASCO® 2026 Highlights: Presenter Vignette – Erika Hamilton
Targeted Oncology 6/2/26 Tucatinib Maintenance Improves PFS Across Key
Subgroups in HER2+ MBC
VJOncology 6/8/26 Breast Cancer Updates at ASCO 2026: KEYNOTE-522,
SERENA-6, and More
VJOncology 6/8/26 HER2CLIMB-05: Subgroup Analyses of Tucatinib,
Trastuzumab & Pertuzumab in HER2+ mBC
VJOncology 6/8/26 Optimizing Sequencing & Maintenance Strategies in HER2+
Metastatic Breast Cancer
VUMEDI 6/8/26 ASCO® 2026 Insights: HER2-Positive mBC 1L
Maintenance - HER2CLIMB-05 Tucatinib + HP Trial Data
and Practice Implications
VUMEDI 6/8/26 ASCO® 2026 Highlights: Breast Cancer - Integrating IO,
Oral SERDs, and ADCs Into 1L Care
Erika Hamilton, MD
SCRI
